Sources of Funding
All research carried out within the Women's Health Research Program in the School of Public Health and Preventive Medicine, Monash University is approved by the Monash University Human Ethics Committee. For studies involving patients attending the Alfred Hospital site, approval is also required from the Human Ethics Committee of the Alfred Hospital. As part of this approval process ALL sources of funding are clearly stated.
Sources of research funding include:
The main source of funding for the Women's Health Research Program is from the National Health and Medical Research Council (NHMRC) of Australia (Prof Susan Davis, Postdoctoral Fellows and PhD Students), competitive research grants from philanthropic trusts and investigator-initiated studies with industry support.
Funding for the Bupa Health Foundation Health and Wellbeing after Breast Cancer Study is from: Bupa Health Foundation, The L.E.W. Carty Trust, Roy Morgan Research and Connie & Craig Kimberley.
We receive funding for the ATLAS (Adjuvant Tamoxifen Longer Against Shorter) study from the Clinical Trial Services and Epidemiological Studies Unit, Oxford UK.
We have received funding for the study Improving the health of Australian Women at Midlife from the Bupa Health Foundation
We have received funding for the study Determining Bone Health in Women at Midlife - a study of factors influencing bone health from Osteoporosis Australia
Other sources of support include:
- A randomised controlled trial of the effects of testosterone on cognitive performance: The Mason Foundation and BioSante USA
- A randomised controlled trial of the effects of HRT versus placebo on cognitive performance: Bayer Healthcare
- Metformin for the management of insulin resistance in overweight women at midlife: Bupa Health Foundation
- The effects of metformin on the LKB1/AMPK pathway in breast tissue, a randomized clinical trial: Faculty of Medicine, Nursing & Health Sciences, Monash University
- A Placebo-Controlled, Randomized, Double-Blind, Parallel-Group, Dose-Finding Trial to Evaluate the Efficacy and Safety of TBS-2 Intranasal Testosterone Gel in Pre-Menopausal Women with Acquired Female Orgasmic Disorder: Trimel Pharm
Other financial disclosures:
Susan Davis has acted as a consultant to BioSante and Trimmel Pharm